ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA FDA approval supports corporate goal. | March 7, 2022
Share this article
Share this article
BOSTON, April 29, 2021 /PRNewswire/ Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that the full peer-reviewed results of the IMproving PlasmA CollecTion (IMPACT) trial have been published in TRANSFUSION, the prime journal for transfusion medicine related research. The publication expands upon the IMPACT trial data presented in October 2020 in a plenary session at the AABB conference. IMPACT, a multicenter, prospective and double-blinded study, is one of the largest randomized controlled trials of plasmapheresis. The trial involved 3,443 donors who underwent 23,137 plasma donations.